Wong Kin Sang – Country Manager, Lundbeck Malaysia
Wong Kin Sang, country manager of Lundbeck Malaysia, walks us through the mental health issues’ perception in Malaysia and the important work Lundbeck has done to bring more awareness to…
Address: Menara Hap Seng, No. 1 & 3,10th Floor, Jalan P Ramlee, 50250 Kuala Lumpur ,Malaysia
Tel: 603-5121 5819
Web: http://www.lundbeck.com/global
We are a research-based company. We engage in research to find new drugs for treatment of CNS disorders, includ ing depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, epilepsy and insomnia.
These are serious disorders. They affect not only patients, but also their families and friends. Besides the stress of having a CNS disorder, patients are often exposed to prejudice because, in many sections of society, there is still far too little understanding of how adversely a CNS disorder affects an individual’s life.
We have taken upon ourselves the task of improving quality of life for persons with a psychiatric or neurological disorder, and we are working intensely to find and develop new and improved drugs. We believe that we can make a significant difference, and we are happy to do so in cooperation with others.
Depression, schizophrenia, Alzheimer’s, Parkinson’s and sleep disorders have their foundation in the central nervous system – our key focus areas. Here are some in depth information to help you better understand these diseases.
Our products
Cipralex® Antidepressant Ebixa® Anti-Alzheimer’s Azilect® Anti-Parkinson’s Serdolect® Schizophrenia Circadin® Insomnia Sabril® Epilepsy Xenazine® Huntington’s disease
Wong Kin Sang, country manager of Lundbeck Malaysia, walks us through the mental health issues’ perception in Malaysia and the important work Lundbeck has done to bring more awareness to…
Lundbeck’s country manager gives a thorough overview of CNS disorders in Malaysia and states: “It is important to remind everyone that mental health conditions or brain diseases are not to…
You have worked in the pharmaceutical industry for many years starting with Novartis and you have spent the last eight years working for Lundbeck. What are the major changes that…
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
The National Heart Institute’s CEO portrays IJN as a national referral center for cardiovascular disease and declares: “IJN is equipped with the best in class technologies and is poised to…
“We believe the future lies with Universal health coverage and the formulation of one and only healthcare, with the merger of public and private sector under one reimbursement system” says…
PEMANDU’s Director for the Healthcare National Key Economic Area gives a thorough understanding of the various entry point projects that were implemented since 2010 to help Malaysia become a high…
Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger…
PhAMA was started in 1972 and now has most of the MNC players among its members which include 43 companies. How has the association evolved since its origin and what…
The pharmaceutical industry has been targeted as one of the key growth sectors for the Malaysian economy under the 10th Malaysia Plan, how successful in your opinion have the government…
Without a doubt, Malaysia shares all the major attributes of an emerging market, from the potential to expand market penetration to the increasing purchasing power of the population. So…
2011 marks the 10th anniversary of the company. Over that time you’ve enjoyed notable success including being the first Asian CRO to attain OECD GLP accreditation. Talk us through your…
Since its origin, Emerging Pharma has been helping foreign pharma companies to enter Malaysia. However, the Malaysian market is relatively small. Why should international pharma companies look to this country…
How would you describe the operating environment for foreign companies to use the services of Malaysian companies and how can you reassure these multinationals that sufficient intellectual property protection is…
Malaysia has good ethnic diversity, cost-effective infrastructure, and highly qualified principal investigators (PIs) and these elements have been in place for a long time. Why is now is the right…
See our Cookie Privacy Policy Here